Bibliography
- Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients diagnosed as having non-hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med 2008;168:469-76
- Sacchi S, Pozzi S, Marcheselli L, Italian Lymphoma Study Group. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer 2007;109:2077-82
- Coiffier B, Thieblemont C, Van Den Neste E, Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etoudes des Lymphomes de l'Adulte. Blood 2010;20:2040-5
- Witzig TE, Gupta M. Signal transduction inhibitor therapy for lymphoma. Hematology (Am Soc Hematol Educ Program) 2010;2010:265-70
- Hans CP, Weisenburger DD, Greiner TC, Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 2005;18:1377-84
- Shipp MA, Ross KN, Tamayo P, Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74
- Graff JR, McNulty AM, Hanna KR, The protein kinase C beta selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462-9
- Podar K, Raab MS, Zhang J, Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615. HCl). Blood 2007;109:1669-77
- Neri A, Marmiroli S, Tassone P, The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma 2008;49:1374-83
- Kuo WL, Liu J, Mauceri H, Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signalling context. Mol Cancer Ther 2010;9:2814-24
- Civallero M, Cosenza M, Neri A, Genomic profiling of enzastaurin treated B cell lymphoma RL cells. Hematol Oncol 2010; [Epub ahead of print]
- Verdelli D, Nobili L, Todoerti K, Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression. Hematol Oncol 2009;27:23-30
- Civallero M, Cosenza M, Grisendi G, Effects of Enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines. Leuk Lymphoma 2010;51:671-9
- Moreau AS, Jia X, Ngo HT, Protein kinase C inhibitor Enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 2007;109:4964-72
- Carducci MA, Musib L, Kies MS, Phase I dose escalation and pharmacokinetic study of Enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006;24:4092-9
- Robertson MJ, Kahl BS, Vose JM, Phase II study of Enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25:1741-6
- Schwartzberg L, Hermann RC, Flinnet IW, Enzastaurin in patients with follicular lymphoma: results of a phase II study [abstract]. J Clin Oncol 2010;28(15S):8040
- Gobrial IM, Harousseau JL, Treon SP, Enzastaurin in previously treated Waldenstrom's Macroglobulinemia: an open-label, multicenter, phase II study [abstract]. Blood 2009;114:3867
- Morschhauser F, Seymour JF, Kluin-Nelemans HC, A phase II study of Enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 2008;19:247-53
- Ysebaert I, Morschhauser F. Enzastaurin hydrochloride for lymphoma. Exp Opin Invest Drugs 2011;20(8):1167-74
- Teeling JL, French RR, Cregg MS, Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793-800
- Mossner E, Brunker P, Moser S, Increasing the efficacy of CD20 antibody therapy through the engineering of a new immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115:4393-402
- Sacchi S, Marcheselli R, Bari A, Phase II study of Velcade® plus Mabthera® in relapsed follicular lymphomas [abstract]. Blood 2010;116:1801
- Fowler NH, McLaughlin P, Hagemeister FB. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma [abstract]. J Clin Oncol 2010;28(15S):8036
- Sacchi S, Cosenza M, Civallero M, Combination of enzastaurin, a PKC inhibitor, and revlimid ® has synergistic activity in non-hodgkin lymphoma [abstract]. Blood 2010;116:4905